Sunshine Biopharma (NASDAQ:SBFMW – Get Free Report) will likely be announcing its resultson Wednesday, August 5th. Analysts expect the company to post earnings of ($1.20) per share and revenue of $8.70 million for the quarter.
Sunshine Biopharma Stock Performance
SBFMW stock opened at $0.06 on Wednesday. Sunshine Biopharma has a 12-month low of $0.02 and a 12-month high of $0.65. The company’s fifty day simple moving average is $0.06 and its 200 day simple moving average is $0.11.
Sunshine Biopharma Company Profile
Sunshine Biopharma is a development-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for oncology and antiviral applications. The company’s research activities encompass the design, synthesis and preclinical evaluation of compounds that inhibit key pathways involved in cell proliferation and viral replication.
Among its lead programs, Sunshine Biopharma is advancing Adva-27a, a topoisomerase II inhibitor licensed from the National Research Council of Canada, which is undergoing preclinical studies for potential use in breast and ovarian cancers.
Recommended Stories
- Five stocks we like better than Sunshine Biopharma
- Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile
- NVIDIA’s OpenAI Backstop Puts AI Financing Risk in Focus
- UPS Just Gave Investors a Second Chance to Buy
- Welltower at 52-Week Highs—But Analysts Believe There’s More to Come
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
